Company Overview and News
KUALA LUMPUR: Guan Chong Bhd , Malton Bhd , Pavilion Real Estate Investment Trust (REIT) and Vicocom International Holdings Bhd are among the stocks to watch on Tuesday, according to JF Apex Research.
KUALA LUMPUR (Aug 13): Pavilion Real Estate Investment Trust (REIT) has been formally invited to participate in the ownership an ongoing development provisionally known as Pavilion Bukit Jalil here by Malton Bhd.
BSMAF 5212 1818
KUALA LUMPUR: Pavilion Real Estate Investment Trust’s (REIT) net property income (NPI) rose 18.1% to RM90.62 million in the second quarter ended June 30, 2018 (2QFY18) from RM76.72 million a year ago, mainly contributed by rental income from Elite Pavilion Mall that was acquired at the end of April.
BSMAF 5212 1818
KUALA LUMPUR: Pantech Group Holdings Bhd , Pavilion Real Estate Investment Trust (REIT) and Ajiya Bhd are among the stocks to watch on Friday, according to JF Apex Research.
KUALA LUMPUR (July 27): The FBM KLCI is expected to consolidate and trend sideways against the backdrop of the mixed overnight close at most global markets, while technology-related stocks may come into focus given the massive sell-off in Facebook shares.
FB 5754 4995 0101 4405 5125 BSMAF 5212 1818
KUALA LUMPUR (July 26): Based on corporate announcements and news flow today, companies that may be in focus on Friday (July 27) may include the following: Tan Chong Motor Holdings Bhd, Utusan Melayu (Malaysia) Bhd, Versatile Creative, Pantech Group Holdings Bhd, TMC Life Sciences Bhd, Pavilion Real Estate Investment Trust, ViTrox Corp Bhd, Ajiya Bhd, Ancom Bhd and Tasek Corp Bhd
5754 4995 0101 5016 4405 5125 BSMAF 5212 1818
KUALA LUMPUR (July 26): Pavilion Real Estate Investment Trust's (REIT) net property income (NPI) rose 18.1% to RM90.62 million in the second quarter ended June 30, 2018 (2QFY18) from RM76.72 million a year ago, mainly contributed by rental income from Elite Pavilion Mall that was acquired at the end of April 2018.
BSMAF 5212 1818
Pavilion Real Estate Investment Trust (July 18, RM1.64) Maintain hold with a higher fair value (FV) of RM1.60: We maintain our “hold” recommendation on Pavilion Real Estate Investment Trust (REIT) with a higher FV of RM1.60 from RM1.53 based on an unchanged forward target yield of 5.5%. The upward FV revision is derived from a higher payout ratio of 100% versus 95% previously.
KUALA LUMPUR: JF Apex Research expects ViTrox Corp Bhd , Frontken Corp Bhd , Ireka Corp Bhd , Choo Bee Metal Industries Bhd and Pavilion Real Estate Investment Trust (Reit) to generate trading interest following their latest news.
In a filing with Bursa Malaysia, the company said earnings in the first quarter were bolstered by rental income from Pavilion Kuala Lumpur Mall’s tenants after the repositioning exercise and higher occupancy rate at the Intermark Mall.
BSMAF 5212 1818
Unofficial reports from India’s Economic Times and a few other news portals suggested that IHH Healthcare Bhd is making a voluntary offer to buy the non-promoter shares of Fortis Healthcare Ltd (Fortis).
5225 FORTIS Q0F IHHHF 532843 5212 7066
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...